Efficacy and Safety of Ceftazidime–Avibactam Alone versus Ceftazidime–Avibactam Plus Fosfomycin for the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia: A Multicentric Retrospective Study from the SUSANA Cohort
Wirksamkeit und Sicherheit von Ceftazidim/Avibactam allein versus Ceftazidim/Avibactam plus Fosfomycin zur Behandlung von im Krankenhaus erworbener Pneumonie und beatmungsassoziierter Pneumonie: multizentrische retrospektive Studie aus der SUSANA-Kohorte
Antibiotics · 02.07.2024 · 13 (7) · 616
DOI: 10.3390/antibiotics13070616 ↗Auf einen Blick
Bei 75 Episoden nosokomialer Pneumonie zeigte die Kombination aus Ceftazidim/Avibactam und Fosfomycin keinen Vorteil gegenüber Ceftazidim/Avibactam allein. Zur Sicherheit wurden 3 Ereignisse berichtet.
Fragestellung
Verbessert Fosfomycin in Kombination mit Ceftazidim/Avibactam das Outcome bei HAP oder VAP?
Methode
Retrospektive multizentrische Kohortenstudie aus der SUSANA-Kohorte; HAP oder VAP mit Ceftazidim/Avibactam allein oder plus Fosfomycin für mindestens 72 h.
Ergebnisse
75 Episoden: 34 mit Ceftazidim/Avibactam allein, 41 mit Ceftazidim/Avibactam plus Fosfomycin. Kein Unterschied im 28-Tage-Überleben in der multivariaten Analyse (HR 0,32; 95 %-KI 0,07–1,39).
Einschränkungen
Kleinere und heterogene Stichprobe; weitere Untersuchungen wurden von den Autor:innen gefordert.
Schlussfolgerung der Autor:innen
Die Autor:innen fanden keinen signifikanten Zusammenhang zwischen Kombinationstherapie und Mortalität.
Kernaussagen
- 75 Episoden nosokomialer Pneumonie wurden analysiert
- Kein Unterschied im 28-Tage-Überleben zwischen den Gruppen
- 3 unerwünschte Ereignisse wurden berichtet
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 02.07.2024. Verfasst von Marco Fois und 18 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Pneumonieprophylaxe
Abstract (Originalsprache)
Hospital-acquired pneumonia (HAP) and ventilation-associated pneumonia (VAP) are challenging clinical conditions due to the challenging tissue penetrability of the lung. This study aims to evaluate the potential role of fosfomycin (FOS) associated with ceftazidime/avibactam (CZA) in improving the outcome in this setting. We performed a retrospective study including people with HAP or VAP treated with CZA or CZA+FOS for at least 72 h. Clinical data were collected from the SUSANA study, a multicentric cohort to monitor the efficacy and safety of the newer antimicrobial agents. A total of 75 nosocomial pneumonia episodes were included in the analysis. Of these, 34 received CZA alone and 41 in combination with FOS (CZA+FOS). People treated with CZA alone were older, more frequently male, received a prolonged infusion more frequently, and were less frequently affected by carbapenem-resistant infections (p = 0.01, p = 0.06, p < 0.001, p = 0.03, respectively). No difference was found in terms of survival at 28 days from treatment start between CZA and CZA+FOS at the multivariate analysis (HR = 0.32; 95% CI = 0.07–1.39; p = 0.128), while prolonged infusion showed a lower mortality rate at 28 days (HR = 0.34; 95% CI = 0.14–0.96; p = 0.04). Regarding safety, three adverse events (one acute kidney failure, one multiorgan failure, and one urticaria) were reported. Our study found no significant association between combination therapy and mortality. Further investigations, with larger and more homogeneous samples, are needed to evaluate the role of combination therapy in this setting.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.
- Fondazione ASIA Onlus, 20090 Buccinasco, Italy.
- Clinic of Infectious Diseases, Department of Medicine and Science of Aging, G. D'Annunzio University, Chieti-Pescara, 66100 Chieti, Italy.
- Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.
- School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.
- Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
ORCID-Profile: Marco Fois, Andrea De Vito, Elena Ricci, Katia Falasca, Chiara Molteni, Stefania Piconi, Paolo Maggi, Giuseppe Vittorio De Socio, Paolo Bonfanti, Giordano Madeddu
Zitieren
APA
Fois, M., De Vito, A., Cherchi, F., Ricci, E., Pontolillo, M., Falasca, K., Corti, N., Comelli, A., Bandera, A., Molteni, C., Piconi, S., Colucci, F., Maggi, P., Boscia, V., Fugooah, A., Benedetti, S., De Socio, G. V., Bonfanti, P., & Madeddu, G. (2024). Efficacy and Safety of Ceftazidime–Avibactam Alone versus Ceftazidime–Avibactam Plus Fosfomycin for the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia: A Multicentric Retrospective Study from the SUSANA Cohort. Antibiotics, 13(7), 616. https://doi.org/10.3390/antibiotics13070616
Vancouver
Fois M, De Vito A, Cherchi F, Ricci E, Pontolillo M, Falasca K, et al. Efficacy and Safety of Ceftazidime–Avibactam Alone versus Ceftazidime–Avibactam Plus Fosfomycin for the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia: A Multicentric Retrospective Study from the SUSANA Cohort. Antibiotics. 2024;13(7):616. doi:10.3390/antibiotics13070616
BibTeX
@article{Fois2024,
author = {Fois, Marco and De Vito, Andrea and Cherchi, Francesca and Ricci, Elena and Pontolillo, Michela and Falasca, Katia and Corti, Nicolò and Comelli, Agnese and Bandera, Alessandra and Molteni, Chiara and Piconi, Stefania and Colucci, Francesca and Maggi, Paolo and Boscia, Vincenzo and Fugooah, Aakash and Benedetti, Sara and De Socio, Giuseppe Vittorio and Bonfanti, Paolo and Madeddu, Giordano},
title = {Efficacy and Safety of Ceftazidime–Avibactam Alone versus Ceftazidime–Avibactam Plus Fosfomycin for the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia: A Multicentric Retrospective Study from the SUSANA Cohort},
journal = {Antibiotics},
year = {2024},
volume = {13},
number = {7},
pages = {616},
doi = {10.3390/antibiotics13070616}
}
EUVIMED